ATE424458T1 - Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung - Google Patents

Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung

Info

Publication number
ATE424458T1
ATE424458T1 AT01946701T AT01946701T ATE424458T1 AT E424458 T1 ATE424458 T1 AT E424458T1 AT 01946701 T AT01946701 T AT 01946701T AT 01946701 T AT01946701 T AT 01946701T AT E424458 T1 ATE424458 T1 AT E424458T1
Authority
AT
Austria
Prior art keywords
polypeptides
present
methods
vegf
nucleic acids
Prior art date
Application number
AT01946701T
Other languages
English (en)
Inventor
Napoleone Ferrara
Colin Watanabe
William Wood
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE424458T1 publication Critical patent/ATE424458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
AT01946701T 2000-06-23 2001-06-22 Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung ATE424458T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21363700P 2000-06-23 2000-06-23
US23097800P 2000-09-07 2000-09-07
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
ATE424458T1 true ATE424458T1 (de) 2009-03-15

Family

ID=26908256

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946701T ATE424458T1 (de) 2000-06-23 2001-06-22 Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung

Country Status (13)

Country Link
US (4) US20020172678A1 (de)
EP (2) EP2075334B1 (de)
JP (1) JP5081361B2 (de)
KR (1) KR100871735B1 (de)
CN (2) CN1449445B (de)
AT (1) ATE424458T1 (de)
AU (3) AU6871401A (de)
CA (1) CA2412612C (de)
DE (1) DE60137847D1 (de)
DK (1) DK1294876T3 (de)
ES (1) ES2323569T3 (de)
MX (1) MXPA03000150A (de)
WO (1) WO2002000711A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074897B2 (en) * 1997-06-16 2006-07-11 Genentech, Inc. Pro943 polypeptides
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
WO2002036625A2 (en) 2000-11-03 2002-05-10 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
PL368972A1 (en) * 2001-08-29 2005-04-04 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
SI1916001T1 (sl) * 2002-03-04 2011-10-28 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba
JP2005538695A (ja) * 2002-04-15 2005-12-22 ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア 概日リズム障害を治療するためのスクリーニング法および治療法
DE10229379A1 (de) * 2002-06-26 2004-01-29 Schering Ag EG-VEGF Rezeptor Antagonisten
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7205110B2 (en) * 2002-10-07 2007-04-17 Zymogenetics, Inc. Uses of human Zven antagonists
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7662380B2 (en) * 2003-01-22 2010-02-16 Takeda Pharmaceutical Company Limited ZAQ ligand-1 antibodies and uses thereof
JP4912144B2 (ja) * 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
GB0320238D0 (en) 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
KR100781753B1 (ko) * 2006-05-24 2007-12-04 연세대학교 산학협력단 Ｄｋｋ2를 포함하는 혈관신생을 촉진시키는 방법
WO2008014547A1 (en) * 2006-07-31 2008-02-07 David Le Couteur Cells genetically modified to express markers of fenestration and uses thereof
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
WO2014118297A1 (en) * 2013-01-30 2014-08-07 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
WO2014201283A1 (en) * 2013-06-12 2014-12-18 The Regents Of The University Of California Methods for protecting ovarian function
JP2015127307A (ja) * 2013-12-27 2015-07-09 国立大学法人福井大学 抗ｐｒｏｋ１抗体による大腸癌の治療
JP6320040B2 (ja) * 2013-12-27 2018-05-09 国立大学法人福井大学 抗ｐｒｏｋ１抗体及び抗ｖｅｇｆ抗体併用による大腸癌の治療
EP3551032A4 (de) * 2016-12-12 2020-12-30 GI Dynamics, Inc. Verfahren zur beurteilung einer behandlung mit einem gastrointestinalen implantat
RU2662944C1 (ru) * 2017-02-17 2018-07-31 Общество с ограниченной ответственностью "Группа развития "АПЕКС" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена prok 1 и/или уменьшением количества белка прокинетицина 1 на основе генно-терапевтических субстанций с геном prok 1, способ получения и использования
US11793889B2 (en) * 2018-09-24 2023-10-24 Kinase Pharma Inc. Methods for selective kinase inhibition by endogenously produced antagonists of one or more kinases
CN112481195B (zh) * 2020-06-09 2021-07-06 首都医科大学附属北京朝阳医院 一种肺动脉组织单细胞悬液及其制备方法和应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5009772A (en) 1989-02-27 1991-04-23 Kerr-Mcgee Corporation Solvent extraction process
EP0462145B1 (de) 1989-03-07 1994-04-27 Genentech, Inc. Kovalente konjugate von lipiden und oligonukleotiden
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
WO1990013641A1 (en) 1989-05-10 1990-11-15 Sloan-Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1991006629A1 (en) 1989-10-24 1991-05-16 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
EP0586505A1 (de) 1991-05-14 1994-03-16 Repligen Corporation Heterokonjugat-antikörper zur behandlung von hiv-infektionen
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
JP2879303B2 (ja) 1993-01-14 1999-04-05 佑 本庶 ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ
US5531697A (en) 1994-04-15 1996-07-02 Sims Deltec, Inc. Systems and methods for cassette identification for drug pumps
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
DK0779806T3 (da) 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
NZ310644A (en) 1995-06-07 1999-08-30 Alkermes Inc Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US5858682A (en) * 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
US6013780A (en) 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5824504A (en) 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
WO1998039448A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
WO1998042741A2 (en) 1997-03-25 1998-10-01 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US7074897B2 (en) 1997-06-16 2006-07-11 Genentech, Inc. Pro943 polypeptides
EP1000148A2 (de) * 1997-08-01 2000-05-17 Genset 5' ests für sekretierte proteine die in der prostata expremiert werden
DE19811194A1 (de) 1998-03-10 1999-09-16 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Prostatagewebe
DE19817557A1 (de) 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe
JPH11332571A (ja) 1998-05-29 1999-12-07 Taisho Pharmaceut Co Ltd 新規遺伝子とそれにコードされる蛋白質
CA2328895A1 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002524040A (ja) 1998-08-03 2002-08-06 ノバルティス アクチエンゲゼルシャフト 造血の制御における新規遺伝子
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1173456A4 (de) * 1999-03-01 2005-10-12 Millennium Pharm Inc Sekretierte proteine und sie kodierende nukleinsäuren
WO2000070049A2 (en) * 1999-05-19 2000-11-23 Incyte Genomics, Inc. Extracellular signaling molecules
AU3246100A (en) * 1999-06-02 2000-12-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
ATE478145T1 (de) * 1999-06-02 2010-09-15 Genentech Inc Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
EP1230362A2 (de) * 1999-11-16 2002-08-14 ZymoGenetics, Inc. Menschliche zven proteine
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
EP1672070A3 (de) * 1999-12-01 2006-10-04 Genentech, Inc. Sekretierte und transmembrane Polypeptide, sowie dafür codierende Nukleinsäuren
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
JP4912144B2 (ja) * 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用

Also Published As

Publication number Publication date
CN101269214A (zh) 2008-09-24
DE60137847D1 (de) 2009-04-16
US8557238B2 (en) 2013-10-15
CN1449445A (zh) 2003-10-15
MXPA03000150A (es) 2003-09-22
US7727536B2 (en) 2010-06-01
US20020172678A1 (en) 2002-11-21
JP2004511432A (ja) 2004-04-15
US20070122412A1 (en) 2007-05-31
KR100871735B1 (ko) 2008-12-03
US20100254999A1 (en) 2010-10-07
WO2002000711A2 (en) 2002-01-03
US7446168B2 (en) 2008-11-04
CN101269214B (zh) 2013-09-04
KR20030011104A (ko) 2003-02-06
AU6871401A (en) 2002-01-08
EP1294876B1 (de) 2009-03-04
CA2412612C (en) 2013-04-30
ES2323569T3 (es) 2009-07-21
HK1059452A1 (en) 2004-07-02
EP2075334B1 (de) 2013-11-20
AU2001268714B2 (en) 2006-09-21
AU2006252241A1 (en) 2007-01-25
CN1449445B (zh) 2012-07-18
US20050064522A1 (en) 2005-03-24
AU2006252241B2 (en) 2010-03-04
WO2002000711A3 (en) 2002-06-20
HK1132298A1 (en) 2010-02-19
EP1294876A2 (de) 2003-03-26
EP2075334A1 (de) 2009-07-01
JP5081361B2 (ja) 2012-11-28
CA2412612A1 (en) 2002-01-03
DK1294876T3 (da) 2009-06-02

Similar Documents

Publication Publication Date Title
ATE424458T1 (de) Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
ATE417063T1 (de) Sekretierte transmembranproteine und dafür kodierende nukleinsäuren
DK1386931T3 (da) Human neurotriminhomolog
DK1241180T3 (da) Humant A33 antigen-lignende protein og nucleinsyrer, der koder for dette
DE69926415D1 (de) Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren
DK1241251T3 (da) Humant prostasin-lignende protein og nukleinsyrer kodende for samme
DK1300417T3 (da) Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor
DE69930422D1 (de) Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren
DK1591452T3 (da) Secernerede og transmembrane polypeptider og nukleinsyrer kodende for samme
DK1241184T3 (da) Humant synaptogyrin-lignende protein og nukleinsyrer kodende for dette
DK1241183T3 (da) Humant HCAR-agtig protein og nucleinsyrer kodende derfor
ATE363537T1 (de) Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure
ATE447026T1 (de) Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure
ATE282047T1 (de) Polypeptide und dafür kodierende nukleinsäure
ATE268819T1 (de) Pro241 polypeptide und dafür kodierende nukleinsäuren
ATE291085T1 (de) Polypeptide und dafür kodierende nukleinsäure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties